Preventing Lead Poisoning in Young Children
Vernon N. Houk, M.D., Director
Henry Falk, M.D., Director
Sue Binder, M.D., Chief
NOTE: Use of trade names is for identification purposes only and does not constitute endorsement by the Public Health Service or by the Department of Health and Human Services.
Table of Contents:
Advisory Committee On Childhood Lead Poisoning Prevention - Members and Consultants
Conversion to Systeme International (SI) Units
- Summary
- Effects of Lead on Children and Fetuses
- Absorption of Lead
- Blood Lead Levels in the United States
- References
Chapter 3. Sources and Pathways of Lead Exposure
- Introduction
- Lead-based Paint
- Soil and Dust
- Drinking Water
- Occupations and Hobbies
- Airborne Lead
- Food
- Other Sources
- Sources of Lead Outside the United States
- References
Chapter 4. The Role of the Pediatric Health-Care Provider
- Anticipatory Guidance
- Screening for Childhood Lead Poisoning
- Doing Appropriate Diagnostic Blood Lead Testing
- Interpretation of Blood Lead Levels
- Educating Parents about Reducing Blood Lead Levels
- Coordinating with Public Sector Officials
- Appropriate Followup
Chapter 5. The Role of State and Local Public Agencies
- Summary
- Suggested Priorities for Screening
- Screening Method
- Anticipatory Guidance and Assessing Risk
- Screening Schedule
- Classification on the Basis of Screening Test Results
- Measurement of Blood Lead Levels
- Erythrocyte Protoporphyrin (EP)
- References
- Summary
- Symptoms of Lead Poisoning
- Evaluation of the Child with a Blood Lead Levels > or = to 20 µg/dL
- Pharmacology of Chelating Agents
- Treatment Guidelines for Children with Blood Lead Levels > or = to 20 µg/dL
- Post-chelation Followup
- Research Areas and Future Trends in the Management of Childhood Lead Poisoning
- References
Chapter 8. Management of Lead Hazards in the Environment of the Individual Child
Chapter 9. Management of Lead Hazards in the Community
- Surveillance
- Risk Assessment and Integrated Prevention Planning
- Outreach and Education
- Infrastructure Development
- Hazard Abatement
Appendix I. Capillary Sampling Protocol
- A. Needed Materials
- B. Preparing for Blood Collection
- C. Preparing the Finger for Puncture
- D. Puncturing of the Finger and Forming Drops of Blood
- E. Filling the Collection Container
- References
Appendix II. Summary for the Pediatric Health-Care Provider
- Chapters 1 and 2. Introduction and Background
- Chapter 3. Sources and Pathways of Lead Exposure
- Chapter 4. The Role of the Pediatric Health-Care Provider
- Chapter 5. The Role of State and Local Public Agencies
- Chapter 6. Screening
- Chapter 7. Diagnostic Evaluation and Medical Management of Children with Blood Lead Levels > or = to 20 µg/dL
- Chapter 8. Management of Lead hazards in the Environment of the Individual Child
- Chapter 9. Management of Lead Hazards in the Community
- Table 1-1. Interpretation of Blood Lead Test Results and Follow-up Activities: Class of Child Based on Blood Lead Concentration
- Table 3-1. Industries Identified by Surveillance for Elevated Blood Lead Levels, California and New York, 1991
- Table 6-1. Priority Groups for Screening
- Table 6-2. Assessing the Risk of High-Dose Exposure to Lead—Sample Questionnaire
- Table 6-3. Class of Child and Recommended Action According to Blood Lead Measurement
- Table 6-4. Suggested Timetable for Confirming Capillary Blood Lead Results with a Venous Blood Lead Measurement
- Table 7-1. Chelating Agents Used in Treating Children with Lead Poisoning
- Figure 2-1. Lowest Observed Effect Levels of Inorganic Lead in Children
- Figure 2-2. Blood Lead Levels Considered Elevated by the Centers for Disease Control and the Public Health Service
- Figure 2-3. Blood Lead Levels and IQ Scores of Children, from Cross-Sectional and Retrospective Cohort Studies
- Figure 2-4. Cumulative Frequency Distribution of Verbal IQ Scores in Children with High and Low Tooth Lead Levels
- Figure 2-5. Change in Blood Lead Levels in Relation to a Decline in Use of Leaded Gasoline, 1976-1980
- Figure 6-1. Relationship between Children’s Blood Lead Levels and Housing Age and Condition, Cincinnati
Top of Page
Preface
This is the fourth revision of the statement on Preventing Lead Poisoning in Young Children by the Centers for Disease Control (CDC). The recommendations continued herein are based mainly on the scientific data showing adverse effects of lead in young children at increasingly lower Blood Lead Levels. They are tempered, however, by practical considerations, for example, of the numbers of children echo would require follow up and the resources required to prevent this disease. It is possible that further scientific data and development of infrastructure and technology will result in a lowering of the blood lead level at which interventions are recommended at a future time.
This statement is a departure from previous ones in several ways. Perhaps most important is the emphasis on primary prevention and the need for coordination between pediatric health-care providers and public agencies. This statement reflects the vision expressed in the Department of Health and Human Services' Strategic Plan for the Elimination of Childhood Lead Poisoning, which calls for a concerted, coordinated society wide effort to eliminate this disease.
In writing this statement, we identified several areas where better data are needed in order to provide scientifically sound guidance. These range from evaluating the efficacy of chelation therapy at lower Blood Lead Levels in terms of preventing the adverse effects of lead to developing science-based criteria for determining when an abated unit is cleaned up enough for rehabilitation. We hope that the appropriate research to answer such questions will be conducted in a timely manner, and we will continue to update the statement to reflect current understanding.
We are aware of concerns about the impact the changes in the statement will have on childhood lead poisoning prevention programs, laboratories, and pediatric health-care providers. In this new statement, we recognize the need for a transition period until we are able to implement fully the new recommendations; it will take time and a concerted effort to implement this new guidance.
CDC is conducting several activities which bear directly on the implementation of the statement. First, as noted above, the Strategic Plan for the Elimination of Childhood Lead Poisoning was released by Dr. Louis W. Sullivan, Secretary of the Department of Health and Human Services, on February 21, 1991. In addition to laying out the actions needed to eliminate childhood lead poisoning, this plan describes the need for infrastructure and technology development, including for the evaluation of blood and environmental lead levels. Second, CDC is aggressively pursuing research and development efforts in collaboration with several instrument manufacturers to develop a field-rugged, relatively inexpensive, and simple-to-operate blood lead instrument, which would markedly enhance blood lead screening efforts. Initial results are encouraging, but the effort is still in the developmental stage. If all goes well, new instrumentation could be ready in 2 to 3 years. Third, we are continuing our efforts to help laboratories improve the quality of their blood lead measurements through our proficiency testing program and through our Blood Lead Laboratory Reference System. Finally, CDC also has a grant program in childhood lead poisoning prevention, through which state and local health agencies receive Federal money to screen children for lead poisoning, ensure environmental and medical follow up for poisoned children, and provide education about lead poisoning. By the end of FY 1991, we will be funding 13 state and 2 city childhood lead poisoning prevention programs, and the President's budget for 1992 includes almost a doubling of the FY 1991 budget. We continue to encourage CDC-funded programs to address infrastructure issues.
Other Federal agencies, like the Environmental Protection Agency and the Department of Housing and Urban Development, have also released plans that deal with aspects of the childhood lead poisoning problem. These agencies are also working to build the needed infrastructure for and expand the scientific knowledge on reducing exposure to lead in the environment.
I wish to thank the members of the Committee and consultants, as well as the numerous other people who assisted in the development and revision of this document. I believe this document will be a major landmark in the effort to eliminate childhood lead poisoning from the United States.
Vernon N. Houk, M.D.
Director
National Center for Environmental Health and Injury Control
Top of Page
Advisory Committee on Childhood Lead Poisoning Prevention
Members and Consultants
Chair
John F. Rosen, M.D., Attending Pediatrician, Montefiore Hospital and Medical Center, 111 East 20th Street, Bronx, New York 10467
Executive Secretary
Henry Falk, M.D., Director, Division of Environmental Hazards and Health Effects, National Center for Environmental Health and Injury Control, Centers for Disease Control, Atlanta, Georgia 30333
Members
Evelyn S. Bouden, M.D., Director, Division of Maternal and Child Health, Pennsylvania Department of Health, 725 H & W Building, Harrisburg, Pennsylvania 17108
Beverly Coleman-Miller, M.D., Special Assistant for Medical Affairs, Commission of Public Health, 1660 L Street, N.W., Suite 1204, Washington, D.C. 20036
Ronald L. Fletcher, M.D., Co-Director, Oncology Department, Greene Memorial Hospital, 1141 N. Monroe Drive, Xenia, Ohio 44385
Lynn R. Goldman, M.D., Chief, Environmental Epidemiology and Toxicology Section, Department of Health Services, 5900 Hollis Street, Suite E Emeryville, California 94608
Dwala S. Griffin, Administrator, Division of Preventive Medicine, Louisville-Jefferson County Board of Health, 400 East Gray Street, Louisville, Kentucky 40202
Richard J. Jackson, M.D., Chief, Office of Environmental Health Hazards Assessment, California Department of Health Services, 2151 Berkeley Way, Room 619, Berkeley, California 4704-1071
Rudolph E. Jackson, M.D., Professor and Acting Chairman, Department of Pediatrics, Morehouse School of Medicine, 720 Westview Drive, S.W., Atlanta, Georgia 30310
James C. Keck, President, Leadtec Services, Inc., 522 Beck Avenue, Baltimore, Maryland 21221
Herbert L. Needleman, M.D., Professor of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Iroquois Building, Suite 305, 3600 Forbes Avenue, Pittsburgh, Pennsylvania 15213-2593
Sergio Piomelli, M.D., Director, Babies Hospital, 3959 Broadway, New York, New York 10032
Stephanie L. Pollack, J.D., Attorney, Conservation Law Foundation of New England, 3 Joy Street, Boston, Massachusetts 02108-1497
Knut Ringen, Dr.P.H., Director, Laborers' National Health and Safety Fund, 905 16th Street, NW, Washington, D.C. 20006
Noel V. Stanton, Lead Chemist, Toxicology Section, State Laboratory of Hygiene, 465 Henry Mall, Madison, Wisconsin 53706
Consultants
David Bellinger, Ph.D., Neuroepidemiology Unit, Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115
James J. Chisolm, Jr., M.D., Associate Professor, Francis Scott Key Medical Center, Building G, Room 224, 4940 Eastern Avenue, Baltimore, Maryland 21224
Charles G. Copley, Deputy
Health Commissioner, City of Saint Louis, Department of Health and Hospitals, Office of the Commissioner, 634 N. Grand, P. O. Box 147202, Saint Louis, Missouri 63178Anita S. Curran, M.D., Assistant Dean for Clinical Affairs, Robert Wood Johnson Medical Center, University of Medicine and Dentistry of New Jersey, One Robert Wood Johnson Place, New Brunswick, New Jersey 08903
John W. Graef, M.D., Director, Lead/Toxicology Clinic, The Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115
Phillip J. Landrigan, M.D., Director Division of Environmental and Occupational Medicine, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, New York 10029
John R. Reigart, M.D., Project Pediatrician, S. C. Childhood Lead Poisoning Project, Department of Pediatrics, Children's Hospital, 171 Ashley Avenue, 6th Floor, Charleston, South Carolina 29425
Top of Page
Conversion to Systeme International (SI) Units
0 µg/dL = 0. µmol/L
5 µg/dL = 0.241 µmol/L
10 µg/dL = 0.483 µmol/L
15 µg/dL = 0.724 µmol/L
20 µg/dL = 0.965 µmol/L
25 µg/dL = 1.206 µmol/L
30 µg/dL = 1.448 µmol/L
35 µg/dL = 1.689 µmol/L
40 µg/dL = 1.930 µmol/L
45 µg/dL = 2.172 µmol/L
50 µg/dL = 2.413 µmol/L
55 µg/dL = 2.654 µmol/L
60 µg/dL = 2.896 µmol/L
65 µg/dL = 3.137 µmol/L
70 µg/dL = 3.378 µmol/L
Erythrocyte Protoporphyrin
1.0 µg/dL = 0.01778 µmol/L 1.0 µmol/L = 56.25 µg/dL
28 µg/dL = 0.498 µmol/L
35 µg/dL = 0.622 µmol/L
70 µg/dL = 1.245 µmol/L
Top of Page
- Page last reviewed: October 1, 1991
- Page last updated: October 1, 1991
- Content source:
National Center for Environmental Health, Division of Emergency and Environmental Health Services